Beta2-agonists for chronic obstructive pulmonary disease (COPD)

References

Citations

1. Kerstjens H, et al. (2005). Chronic obstructive pulmonary disease. Clinical Evidence (13): 1923-1947.

2. Stoller JK (2002). Acute exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine, 346(13): 987–994.

3. Calverley PM, et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 356(8): 775–789.

4. Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.

5. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2005). Executive summary (updated 2005). In Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online: http://www.goldcopd.com/GuidelinesResources.asp?I1=2&I2=0.

Author:	Maria G. Essig, MS, ELS	Last Updated: May 8, 2008
Medical Review:	Caroline S. Rhoads, MD - Internal Medicine Ken Y. Yoneda, MD - Pulmonology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.